Travere Therapeutics, Inc. (TVTX) SEC Filings, Feb 5-20, 2026

Travere Therapeutics files its annual report describing a rare‑disease focused biopharma business built around FILSPARI and a growing pipeline. The company now has full FDA approval for FILSPARI to slow kidney function decline in adults with IgA nephropathy and is pursuing an additional indication in focal segmental glomerulosclerosis, with a supplemental application under FDA review and an April 13, 2026 PDUFA date.

Travere is also advancing pegtibatinase in a pivotal Phase 3 trial for classical homocystinuria after resolving manufacturing scale‑up issues and restarting enrollment in 2026. Existing revenue comes from rare kidney and metabolic products, including Thiola/Thiola EC, though these face generic competition. Globally, Travere relies on partners CSL Vifor and Chugai for FILSPARI commercialization outside the United States and highlights extensive patent and orphan‑drug exclusivity intended to protect key assets.

Travere Therapeutics, Inc. executive Elizabeth E. Reed, the Chief Legal Officer and General Counsel, reported option exercises and share sales in Travere stock. On February 17, 2026, she exercised an employee stock option for 10,000 shares, acquiring the same number of Travere common shares at a reported exercise price of $19.08 per share. The option, granted on January 4, 2017 and expiring on January 4, 2027, is fully vested and exercisable. On the same date, she sold 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262, in each case under a prearranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, she directly owns 105,211 shares of Travere common stock.

Travere Therapeutics reported strong growth for 2025 driven by its kidney drug FILSPARI. Fourth-quarter U.S. net product sales were $126.6 million, up from $73.5 million a year earlier, with FILSPARI contributing $103.3 million, a 108% increase. Full-year U.S. net product sales reached $410.5 million, compared with $226.7 million in 2024, including FILSPARI net product sales of $322.0 million, up 144%.

GAAP net income for Q4 2025 was $2.7 million, versus a loss of $60.3 million in Q4 2024, while full-year GAAP net loss narrowed to $25.5 million from $321.5 million. On a non-GAAP basis, the company reported Q4 net income of $33.3 million and full-year 2025 net income of $81.1 million.

Cash, cash equivalents and marketable securities totaled $322.8 million as of December 31, 2025, and Travere expects a $25 million sales-based milestone from Mirum in the first half of 2026. The FDA is reviewing a supplemental application for FILSPARI in FSGS with a PDUFA target action date of April 13, 2026. Enrollment has resumed in the Phase 3 HARMONY trial of pegtibatinase for classical homocystinuria.

Armistice Capital, LLC and Steven Boyd filed Amendment No. 8 to a Schedule 13G/A reporting beneficial ownership of 3,763,891 shares of Travere Therapeutics, Inc.

The filing states this equals 4.21% of the class and shows shared voting and shared dispositive power over 3,763,891 shares as of 12/31/2025. The filing is a joint reporting statement by Armistice Capital (investment manager to the Master Fund) and Steven Boyd, dated 02/17/2026.

Elizabeth Reed has filed a notice of intent to sell 10,000 shares of TVTX common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of February 17, 2026, and an aggregate market value of $278,317.

The 10,000 shares to be sold were acquired the same day through a stock option exercise from the issuer, paid in cash. Over the prior three months, Reed also sold TVTX common shares on several dates, generating gross proceeds ranging from $96,360.09 to $273,420.00 per transaction.

Perceptive Advisors LLC and affiliated entities report a significant minority stake in Travere Therapeutics, Inc. They beneficially own 4,278,180 shares of common stock, representing 4.8% of the company’s outstanding shares, based on 89,472,327 shares outstanding as of October 27, 2025.

The shares are directly held by Perceptive Life Sciences Master Fund, Ltd., with voting and investment power shared among the Master Fund, Perceptive Advisors, and Joseph Edelman. The group certifies the investment was not made to change or influence control of Travere Therapeutics.

Travere Therapeutics Inc. received an amended Schedule 13G/A from Macquarie entities indicating they no longer hold a reportable stake in the company’s common shares. Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report beneficial ownership of 0 shares, or 0.00% of the class, as of 12/31/2025.

The filers state the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics.

Travere Therapeutics Inc received a major shareholder disclosure from State Street Corporation, which reported beneficial ownership of 4,756,666 Travere common shares, representing 5.3% of the class as of December 31, 2025.

State Street reports shared voting power over 4,485,757 shares and shared dispositive power over 4,756,666 shares, with no sole voting or dispositive authority. The position is certified as held in the ordinary course of business and not for changing or influencing control of Travere.

Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock. On February 4, 2026, Inrig sold 1,547 Travere common shares at a weighted average price of $32.11 and an additional 232 shares at a weighted average price of $32.85.

These transactions were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements and include shares sold to cover tax obligations from vesting restricted stock units. Following these sales, Inrig directly held 105,706 Travere common shares.